Results 221 to 230 of about 353,556 (317)

iPRISM: Intelligent Predicting Response to Cancer Immunotherapy through Systematic Modeling

open access: yesAdvanced Intelligent Systems, EarlyView.
The Intelligent Predicting Response to cancer Immunotherapy through Systematic Modeling (iPRISM) model uses data from genes and immune responses to predict how well cancer patients will respond to immunotherapy. Tested on multiple cancer types, iPRISM shows higher accuracy compared to existing methods.
Yinchun Su   +7 more
wiley   +1 more source

Periungual squamous cell carcinoma in childhood: a case report. [PDF]

open access: yesOxf Med Case Reports
Macedo-Pérez M   +4 more
europepmc   +1 more source

Preoperative Extracorporeal Irradiation of the Blood as Adjunctive Immunosuppression in Human Renal Transplantation

open access: green, 1971
Bertil Persson   +5 more
openalex   +2 more sources

Immunosuppression by Leukemia Viruses [PDF]

open access: bronze, 1971
Gloria C. Koo   +2 more
openalex   +1 more source

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

open access: yesCellular & Molecular Immunology, 2019
Kyohei Nakamura, M. Smyth
semanticscholar   +1 more source

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah   +2 more
wiley   +1 more source

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

Home - About - Disclaimer - Privacy